Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing

WEDNESDAY, Oct. 4, 2023 (HealthDay News) -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Related Posts
HIV & Hepatitis Can Be Deadly Combo for the Heart
WEDNESDAY, Sept. 21, 2022 (HealthDay News) -- As people with HIV age, their odds...
In Mouse Study, Scientists Use Gene Editing to Reverse a Major Cause of Blindness
FRIDAY, March 17, 2023 (HealthDay News) -- A gene-editing experiment that...
Septoplasty Effective for Nasal Obstruction Linked to Deviated Septum
THURSDAY, Oct. 19, 2023 (HealthDay News) -- For adults with nasal obstruction...
Access to Medical Marijuana Won’t Lower Use of Opioid Painkillers: Study
WEDNESDAY, July 5, 2023 (HealthDay News) -- Medical marijuana is touted as a...
